STTR Phase I:High Pressure Disaggregation of IVIg Formulations For Increased Yield and Safety

这个小型企业技术转移研究（STTR）第一阶段项目建议在商业静脉注射免疫球蛋白配方中使用高压对聚集蛋白进行分解和适当的再折叠。该项目的商业应用将是提高静脉给药治疗蛋白的质量。工艺产量的增加将降低IVIg治疗的患者成本，而IVIg配方的总含量显著降低将降低副作用并降低严重并发症的风险。

This Small Business Technology Transfer Research (STTR) Phase I project proposes to use high pressures for disaggregation and proper refolding of aggregated proteins in commercial IVIg (immunoglobins for intravenous administration) formulations. The commercial application of this project will be in improved quality of therapeutic proteins for intravenous administration. Increased process yields will lower patient costs for IVIg therapies, and IVIg formulations with dramatically diminished aggregate content will lower side effects and reduce the risk of severe complications.